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Lung cancer is the leading cause of cancer-related deaths in the
Western world. Small-cell lung carcinoma (SCLC) accounts for
about 20% of all cases of lung cancer (Ihde, 1995). Although the
introduction of modern chemotherapeutic agents and improved
techniques in radiotherapy increased the survival rate of SCLC
patients, there is a continued need for the development of novel
therapeutic strategies. The use of targeted cytotoxic analogues
represents a modern approach to the treatment of various cancers
because it may improve tumour inhibition and decrease the toxi-
city (Schally and Nagy, 1999). Typically, targeted agents consist of
a toxic moiety conjugated to a ligand possessing a high affinity for
tumour cells. Certain molecules such as enzymes, antigens, or
receptors that are expressed predominantly on the surface of
cancer cells may be used as targets to increase the selectivity of
therapy (Pastan and FitzGerland, 1991).
SCLC is a neuroendocrine tumour. Many SCLC tumours and
cell lines express high levels of bombesin-like peptides and/or
specific high-affinity binding sites for bombesin. An autocrine role
for bombesin-like peptides in stimulating the growth of some
SCLC tumours has been suggested (Cuttitta et al, 1985; Moody
et al, 1985; Moody and Cuttitta, 1993; Pinski et al, 1994; Koppán
et al, 1998). Chronic treatment with bombesin antagonists
significantly inhibits the proliferation of SCLC in vivo and in vitro
(Pinski et al, 1994; Koppán et al, 1998). Molecular cloning
revealed the presence of three distinct bombesin receptors in
humans. Bombesin receptor subtype-1 (hGRPR/BRS-1) binds
gastrin-releasing peptide (GRP), and hNMBR/BRS-2 is preferen-
tially activated by neuromedin B (Von Schrenck et al, 1989;
Spindel et al, 1993). BRS-3 is considered an orphan receptor
because its natural ligand remains unknown (Fathi et al, 1993).
The existence of a fourth subtype of bombesin receptor (BRS-4)
has also been predicted in mammals, after the identification of
BRS-4 in frogs (Nagalla et al, 1995). Bombesin receptors belong
to the superfamily of the seven-transmembrane domain receptors
and are involved in signal transduction pathways by hydrolysing
GTP (Spindel et al, 1993) and stimulating the expression of c-fos
and c-jun mRNAs (Draoui et al, 1994).
Considering that bombesin receptors have been detected in
approximately 95% of SCLCs (Toi-Scott et al, 1996), these
binding sites could be used for targeting of cytotoxic bombesin
analogues. Thus, we recently developed a cytotoxic analogue of
bombesin AN-215 (Nagy et al, 1997), which consists of a potent
cytotoxic derivative of doxorubicin (DOX), 2-pyrrolino-DOX
(AN-201) (Nagy et al, 1996), covalently linked to the carrier
octapeptide RC-3094 (Gln–Trp–Ala–Val–Gly–His–Leu–Y(CH2-
NH)–Leu–NH2) (Nagy et al, 1997). AN-215 shows high affinity to
bombesin receptors on Swiss 3T3 cells and it retains the anti-
proliferative effect of its cytotoxic moiety (Nagy et al, 1997).
NCI-H-69 cell line is an important model of SCLC and when
xenografted into nude mice expresses bombesin receptors. In this
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Summary Recently, we developed a powerful cytotoxic analogue of bombesin AN-215, in which the bombesin-like carrier peptide
Gln–Trp–Ala–Val–Gly–His–Leu–Y(CH2-NH)–Leu–NH2 (RC-3094) is conjugated to a potent derivative of doxorubicin, 2-pyrrolinodoxorubicin
(AN-201). Small-cell lung carcinomas (SCLCs) are known to express high levels of bombesin receptors. We evaluated whether these
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of RC-3094 and AN-201. The levels of mRNA for bombesin receptor subtypes were evaluated by reverse transcription-polymerase chain
reaction. In vitro, both the analogue AN-215 and the radical AN-201 showed strong antiproliferative effects on H-69 cells, AN-215 requiring
more time to exert its action at 10–8 M concentration than AN-201. In vivo, the growth of H-69 SCLC tumours was significantly inhibited by the
treatment with 200 nmol kg–1 of AN-215, while equimolar doses of the cytotoxic radical AN-201 or the mixture of AN-201 and the carrier
peptide were toxic and produced only a minor tumour inhibition as compared with control groups. mRNA for bombesin receptor subtypes 2
(BRS-2) and 3 (BRS-3) was detected in H-69 tumours. The mRNA levels for BRS-3, but not for BRS-2, were lower in the AN-215-treated
tumours as compared with controls. Our results demonstrate that the cytotoxic bombesin analogue AN-215 could be considered for targeted
therapy of tumours, such as SCLC, that express bombesin receptors. © 1999 Cancer Research Campaign
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study we evaluated the antiproliferative activity of the cytotoxic
bombesin analogue AN-215 in vivo and in vitro.
MATERIALS AND METHODS
Peptides and cytotoxic radical
Cytotoxic radical 2-pyrrolino-DOX (AN-201), the bombesin-
like carrier analogue Gln–Trp–Ala–Val–Gly–His–Leu–Y(CH2-
NH)–Leu–NH2 (RC-3094) and the cytotoxic bombesin analogue
2-pyrrolino-DOX-14-O-hemiglutarate linked to the amino
terminal of Gln–Trp–Ala–Val–Gly–His–Leu–Y(CH2-NH)–
Leu–NH2 (AN-215) were synthesized in our laboratory as
described (Nagy et al, 1997). Before the intravenous (i.v.)
injection, the compounds were dissolved in 5% (w/v) aqueous
D-mannitol solution (Sigma, St Louis, MO, USA).
Cell lines
The human SCLC cell line NCI-H-69 was obtained from
American Type Culture Collection (ATCC, Manassas, VA, USA)
and cultured in RPMI-1640 medium supplemented with 10% fetal
bovine serum (FBS), 2 mM glutamine, penicillin (100 U ml–1),
streptomycin (100 mg ml–1) and amphotericin B (100 U ml–1) at
37°C in a humidified 95% air/5% carbon dioxide atmosphere.
Cells were passaged weekly and routinely monitored for
mycoplasma contamination using a detection kit (Boehringer
Mannheim, Mannheim, Germany). All culture media components
were purchased from Gibco (Grand Island, NY, USA).
MTT assay
The assay was performed as described (Plumb, 1989). Briefly,
cells were seeded into 96-well microplates and cultured for 18 h.
AN-215 and AN-201 were added to the medium in final concen-
trations of 10–9–10–7 M. Control cultures received HITES medium
alone. HITES medium contained RPMI-1640 plus 4 mM glut-
amine, 10 mM HEPES (Gibco, Grand Island, NY, USA), 5 mg ml–1
insulin, 10 mg ml–1 transferrin, 30 nM sodium selenide, 10 nM
hydrocortisone, 10 nM b-oestradiol, all from Sigma (St Louis,
MO, USA). After 72 h of culture, the medium was removed and
200 ml HITES containing 80 mg MTT [3(4,5-dimethylthiazol-2yl)-
2,5-diphenyl tetrazolium bromide; Sigma] was added. The
microplates were incubated for 4 h at 37°C in darkness. The
medium was removed, cells were washed twice with RPMI-1640
and 200 ml dimethyl sulphoxide (DMSO; Sigma) was added
followed by 25 ml of Sorensen’s glycine buffer (0.1 M glycine plus
0.1 M sodium chloride, pH 10.5). After a brief mixing, the plates
were read at 540 nm on the plate reader (Beckman, Palo Alto, CA,
USA). Results were calculated as % T/C, where T = optical
density (OD540 nm) of treated cultures (HITES medium plus
AN-201 or AN-215) and C = OD540 nm of untreated cultures
(HITES medium alone).
Animals
Five- to 6-week-old male athymic (Ncr nu/nu) nude mice were
obtained from National Cancer Institute (NCI; Bethesda, MD,
USA). The mice were housed in sterile cages under laminar flow
hoods in a temperature-controlled room with a 12-h light/12-h
dark schedule and were fed autoclaved chow and water ad libitum.
Their care was in accord with institutional guidelines.
Experimental protocol
NCI-H-69 cells growing exponentially were implanted into three
male nude mice by subcutaneous (s.c.) injection of 107 cells in the
right flank. Tumours resulting after 8 weeks in donor animals were
aseptically dissected and mechanically minced. Three mm3pieces of
tumour tissue were transplanted (s.c.) by trocar needle into 50 mice
under methoxyflurane (Metofane, Pittman-Moore, Mundelein, IL,
USA) anaesthesia. Three weeks after transplantation, when tumours
reached a volume of approximately 45 mm3, mice were randomized
and divided into five experimental groups of 5–7 animals each,
which received the following treatments as a single i.v. injection:
group 1, control, vehicle solution (5% mannitol); group 2, cytotoxic
radical AN-201 at a dose of 200 nmol kg–1; group 3, unconjugated
mixture of the cytotoxic radical AN-201 and the carrier RC-3094 at
a dose of 200 nmol kg–1; group 4, cytotoxic analogue AN-215 at a
dose of 200 nmol kg–1; group 5, carrier peptide RC-3094 at a dose of
200 nmol kg–1. All experiments were approved by the institutional
ACUC and the procedures were essentially in accordance with
UKCCCR guidelines (1998) for the welfare of animals in experi-
mental neoplasia.
Histological methods
Tumour samples were processed as described (Szepeshazi et al,
1992). The extent of necrosis was evaluated with the point-
counting method on tumour slides stained with haematoxylin and
eosin (H&E). For the measurement of the number of mitotic and
apoptotic cells, ten high-power fields were considered and the
numbers of mitotic and apoptotic cells per 1000 cells (mitotic
and apoptotic indices) were calculated in H&E-stained slides.
RNA extraction
Total RNA was isolated using the RNAzol B reagent (TEL-TEST,
Inc., Friendswood, TX, USA) following the manufacturer’s
instructions. The quantity and the quality of the RNA was
assessed by spectrophotometry at 260 nm and 280 nm
(O.D.260/O.D.280 > 1.8).
Reverse transcription
One microgram of total RNA was added in a test tube containing
10 mM Tris–HCl (pH 8.3), 50 mM potassium chloride (KCl),
5m M magnesium chloride (MgCl2), 1 mM each of deoxyribo-
nucleoside triphosphate, 2.5 mM random hexamers, 1 U RNAase
inhibitor and double-distilled water in a final volume of 19 ml.
Following heating for 10 min at 65°C and quenching on ice, 2.5 U
Moloney murine leukaemia virus reverse transcriptase (Perkin-
Elmer, Norwalk, CT, USA) were added and the reaction mixture
was incubated for 10 min at room temperature following incuba-
tion at 42°C for 1 h. The reaction was terminated by heating at
95°C for 5 min and quenching on ice.
Polymerase chain reaction (PCR) amplification
One microlitre of the cDNA was amplified in a 50 ml solution
containing 10 mM Tris–HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2,
200 mM of each dNTP, 2.5 U Taq DNA polymerase (Perkin-Elmer,
Norwalk, CT, USA) and 0.4 mM of each primer. The primers
used were 5¢-TCCTCTGACTTCAACAGCGACACC-3¢ and5¢-TCTCTCTTCCTCTTGTGCTCTTGG-3¢ for human glycer-
aldehyde-3-phosphate dehydrogenase (hGAPDH), 5-ATTTG-
GCAGGATTGGCTGC-3¢ and 5¢-TGAGGCAGATCTTCATCAG-3
for BRS-1 (GRP receptor, GRPR), 5¢-CGGACTCTGCTG-
GAAAGGA-3¢ and 5¢-GACGTCTGCATGTCCATGG-3 for
BRS-2 (neuromedin B receptor, hNMBR) and 5¢-GCTCTGTG-
GTTTCTAACG-3¢ and 5¢-CTGCCTTGTATCTGTCAGC-3¢ for
BRS-3 (Sun and Schally, in preparation). Samples were denatured at
94°C for 5 min and then subjected to 40 cycles of 94°C for 1 min
(denaturation), 52°C for 1 min (annealing) and 72°C for 1 min
(extension) for BRS-1 and BRS-3, 94°C for 30 s, 62°C for 30 s and
72°C for 30 s for BRS-2 or 26 cycles of 94°C for 35 s, 58°C for 40 s
and 72°C for 40 s for hGAPDH, followed by a final extension at
72°C for 5 min using a Perkin-Elmer DNA thermal cycler model
2400. The number of cycles was determined in preliminary experi-
ments to be within the exponential range of PCR amplification. Five
microlitres of each PCR product were electrophoresed in an 8%
polyacrylamide gel, stained with silver and quantified densitometri-
cally using a scanning densitometer (Model GS-700, BioRad, CA,
USA) coupled with the BioRad PC analysis software. The mRNA
levels of each bombesin receptor subtype were normalized versus the
corresponding levels of hGAPDH.
Statistical analysis
The data are expressed as the mean ± s.e.m. Statistical evaluation
of data was performed by Student’s t-test (two-tailed) and
Duncan’s multiple range test. The SigmaPlot computer software
(Jandel, San Rafael, CA, USA) was used for preparation of
figures.
RESULTS
Anti-tumour effects and toxicity
Administration of a single i.v. injection of cytotoxic bombesin
analogue AN-215 produced a significant (P < 0.05) growth inhibi-
tion of NCI-H-69 SCLC xenografted into nude mice (Figure 1).
Twenty-eight days after the injection the tumour volume in the
animals treated with AN-215 was significantly reduced to 
242.2  ± 86.9 mm3 (P < 0.05) (Table 1) as compared with the
control group which measured 817.9 ± 206.5 mm3. Tumour inhibi-
tion produced by the treatment with an equimolar dose of AN-201
(Figure 1 and Table 1) was not significant and accompanied by
high toxicity; five of six animals were dead in the AN-201-treated
group, while only one of six mice died in the AN-215-treated
group before the termination of the experiment. A high toxicity
was also found in the group that received the unconjugated
mixture of AN-201 and carrier RC-3094, five of seven mice being
dead 28 days after the treatment. Administration of the carrier
peptide was not toxic, but had no significant tumour inhibitory
effects. A significant loss of body weight occurred in all groups
injected with cytotoxic agents. The reduction in body weight
produced by AN-215 was smaller and of a shorter duration than
that caused by radical AN-201. The body weights in the surviving
animals recovered within 2 weeks after the injection (Figure 2).
Histology
The quantitative histological data are shown in Table 2. There was
an increase in the apoptotic index and the percentage area of
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Figure 1 Changes in tumour volume in athymic nude mice bearing
subcutaneous xenografts of H-69 SCLC after treatment with 200 nmol kg–1 of
cytotoxic bombesin analogue AN-215, cytotoxic radical AN-201,
unconjugated mixture of AN-201 and the carrier peptide RC-3094, or the
carrier peptide RC-3094. Vertical bars show s.e.m. *P < 0.05 vs control.
†Three mice in the AN-201-treated group died during the fourth week of
treatment and the volume of tumours recorded on day 21 is shown
Table 1 Effect of a single intravenous injection of 200 nmol kg–1 cytotoxic bombesin analogue AN-215, cytotoxic radical AN-
201, carrier peptide RC-3094 and mixture of RC-3094 and AN-201 on tumour volume, tumour weight and animal mortality in
athymic nude mice bearing H-69 SCLC, recorded 28 days later
Substance Initial tumour Final tumour Tumour burden Number of deaths/
volume volume (mg g–1 body weight) number of all
(mm3) (mm3) animals
Control 42.3 ± 7.8 817.9 ± 206.5 31.2 ± 7.2 0/6
AN-201 43.4 ± 6.11 aa 5/6b
AN-201 + RC-3094 40.7 ± 7.3 687.1 ± 276.8 30.2 ± 7.9 5/7
AN-215 38.2 ± 4.8 242.2 ± 86.9* 10.5 ± 3.7 1/6
RC-3094 35.4 ± 8.9 616.8 ± 103.3 22.7 ± 1.7 0/5
aFour mice were alive on day 21, but 3 died before day 26 and the volume of tumours recorded on day 21 was 253 ± 63.2.
The only surviving mouse was sacrificed on day 26 and thus no data on the tumour burden are available. bDeaths until day
26 when the last surviving animal was sacrificed (see also footnote a). *P < 0.05 vs controls.necrosis in tumours of the mice treated with AN-215 as compared
with the tumours in the control group. Although the mitotic index
was elevated in the tumours of the AN-215-treated mice, the ratio
of apoptotic to mitotic indices remained higher than in the
controls. However, the differences between the tumours from the
control and the AN-215-treated mice were not statistically signifi-
cant, probably because the cytotoxic agent was administered
28 days before the histological analysis was performed.
Antiproliferative effect in vitro
The antiproliferative effects produced by the cytotoxic radical
AN-201 and the cytotoxic bombesin analogue AN-215 in H-69
cells cultured in vitro were assessed by the MTT assay. H-69 cells
were exposed to the cytotoxic agents at various concentrations for
periods of 1 min to 24 h. AN-201 and AN-215 had no effect at
10–9 M, while at 10–7 M these cytotoxic agents had similar antipro-
liferative activity (Figure 3A). However, when H-69 cells were
exposed to the compounds at a concentration of 10–8 M, AN-215
required more time than AN-201 to produce a comparable
inhibitory effect (Figure 3B). After 24 h, however, their antipro-
liferative effect was no longer discernible (Figure 3B).
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Figure 2 Changes in body weight of athymic nude mice bearing
subcutaneous xenografts of H-69 SCLC after treatment with 200 nmol kg–1
of cytotoxic bombesin analogue AN-215, cytotoxic radical AN-201,
unconjugated mixture of AN-201 and the carrier peptide RC-3094, or the
carrier peptide RC-3094. Vertical bars show s.e.m. *P < 0.05 vs control,
**P < 0.005. †Three mice in the AN-201 treated-group died during the fourth
week of treatment and the body weight recorded on day 21 is shown
Table 2 Effect of treatment with cytotoxic bombesin analogue AN-215 on some histological characteristics of H-69 SCLC
xenografted into nude mice
Substance % area of necrosis Mitotic index Apoptotic index Ratio of apoptotic
in tumours to mitotic indices
Control 18.1 ± 7.0 8.65 ± 0.35 7.0 ± 2.0 0.82 ± 0.26
AN-215 27.4 ± 10.9 11.4 ± 0.10 11.5 ± 2.1 1.01 ± 0.18
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Figure 3 Effect of cytotoxic bombesin analogue AN-215 and cytotoxic radical AN-201 at 10–7 M (A) and 10–8 M (B) on the growth of H-69 SCLC in vitro.
Results are expressed as the percentage of the number of cells found after the treatment with the cytotoxic agents compared to the number of the untreated
cells. Vertical bars show s.e.m. from two independent experiments970 H Kiaris et al
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Expression of mRNA for bombesin receptors
The levels of mRNA for bombesin receptor subtypes
hGRPR/BRS-1, hNMBR/BRS-2 and BRS-3 were analysed in
H-69 SCLC tumours of control and AN-215-treated animals
(Figure 4). Four tumours from each group were used for the
analyses. mRNA for hGRPR/BRS-1 was not found in the control
or the AN-215-treated tumours, but the presence of mRNA for
BRS-2 and BRS-3 was detected. Densitometric analyses of
RT-PCR products revealed that hNMBR/BRS-2 mRNA expres-
sion was 0.48 ± 0.03 arbitrary units (a.u.) in the control group and
0.41 ± 0.03 a.u. in the AN-215-treated group, the decrease of 14%
being not significant. The levels of BRS-3 were 0.72 ± 0.04 a.u. in
the control and 0.45 ± 0.04 a.u. in the AN-215-treated group corre-
sponding to a 31% reduction (P < 0.05).
DISCUSSION
Although some progress has been made in the treatment of SCLC,
the overall therapeutic results are not satisfactory and the develop-
ment of novel treatment modalities is required. In the present study
we evaluated the antitumor effects of targeted cytotoxic bombesin
analogue AN-215, in nude mice bearing xenografts of the human
SCLC cell line H-69. A single i.v. injection of 200 nmol kg–1
AN-215 inhibited significantly the growth of NCI-H-69 tumours
for at least 28 days and caused the death of only one of six animals.
In contrast, treatment with AN-201 or a mixture of AN-201 and
RC-3094 was ineffective and induced 71–83% mortality among
experimental animals within 4 weeks after the injection. The group
treated with the carrier peptide showed no inhibition of the tumour
growth.
Histological evaluation revealed that tumours from mice treated
with AN-215 showed increased apoptotic index and more exten-
sive necrosis as compared to the control group.
High binding affinity of the receptor ligand is required for
efficient targeting of the tumour. The cytotoxic bombesin analogue
AN-215 has been shown to displace binding of [125I-Tyr4]
bombesin to receptors on Swiss 3T3 cells at nanomolar concentra-
tions with a Ki value of 1.6 nM (Nagy et al, 1997). Previously we
demonstrated that isolated membrane fractions of H-69 tumour
cells growing in nude mice display high-affinity binding for
[125I-Tyr4]bombesin (Pinski et al, 1994; Koppán et al, 1998). In this
study, molecular biology analysis at the mRNA level showed that
H-69 tumours express mRNA for BRS-2 and BRS-3 but not for
BRS-1. It has been suggested that the pharmacological properties
of BRS-3 are distinct from those of BRS-1 and BRS-2 (Mantey et
al, 1997). Interestingly, the tumours from the
AN-215-treated group expressed lower levels of BRS-3 as
compared to the controls. This could be the consequence of tumour
inhibition or a direct result of the interaction between the cytotoxic
bombesin analogue and the BRS-3 receptor. Considering that the
treatment consisted of a single i.v. injection of the cytotoxic
analogue 28 days before the mRNA analysis, the down-regulation
of the BRS-3 may be interpreted as a consequence of the tumour
inhibition rather than a direct result of the interaction between the
cytotoxic bombesin analogue and the BRS-3 receptor. A down-
regulation of BRS-3 due to endocrine effects is unlikely because a
low dose of the bombesin analogue AN-215 was used in a magni-
tude of nanomoles. Thus, it is more likely that the down-regulation
of BRS-3 is a result of the suppression of the tumour growth,
implicating BRS-3 as well as its unknown natural ligand in the
autocrine stimulation of the H-69 SCLC. However, these findings
regarding the role of BRS-3 in the growth H-69 SCLC should be
confirmed by more detailed studies. Furthermore, an interaction of
the cytotoxic bombesin analogue AN-215 with receptors other
than the three known subtypes of bombesin receptors should be
also considered as a possibility (Nagalla et al, 1995; Orosz et al,
1995).
In receptor-targeted chemotherapy, the cytotoxic moiety must
retain the anti-tumour activity after conjugation to the carrier
peptide. We have previously demonstrated (Nagy et al, 1996) that
AN-215 preserves the cytotoxic activity of AN-201 in vitro.
2-Pyrrolino-DOX (AN-201) is a daunosamine-modified derivative
of DOX which is 500–1000 times more potent than DOX in vitro.
In vitro, AN-201 inhibited growth of cultured NCI-H-69 cells
faster than AN-215 (Figure 3). This is probably due to differences
in the mechanism of action of these cytotoxic agents. AN-201
could enter the cells by passive diffusion, as described for DOX,
while AN-215 may require an interaction with the bombesin
receptor in order to exert its cytotoxicity. In vitro, a difference in
the cytotoxicity between AN-201 and AN-215 could be demon-
strated at 10–8 M. Addition of 10–9 M AN-201 had no effect, and
10–7 M AN-201 caused the death of approximately 60% of cells
within 1 min of treatment. If the delay in the effect of AN-215 as
compared to AN-201 at a concentration of 10–8 M was due to the
M123 45678
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400 bp–
A M1 2 3 4 5 6 7 8
hGRPR
hNMBR
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Figure 4 Polyacrylamide gel electrophoresis of reverse-transcribed and subsequently PCR-amplified mRNAs for BRS-3 (A) and hGRPR/BRS-1 and
hNMBR/BRS-2 (B) in H-69 SCLC xenografted into nude mice. The bands for corresponding levels of hGAPDH are also shown (A). M, molecular weight DNA
marker; P, positive control; 1–4, untreated tumours; 5–8, AN-215-treated tumours. All PCR amplification reactions yielded products of the expected size which
were 158 bp for BRS-1, 484 bp for BRS-2, 375 bp for BRS-3 and 207 bp for hGAPDH. No expression of BRS-1 was detected, but the mRNA for BRS-2 and
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deconjugation of the cytotoxic radical AN-201, we should have
also observed a retardation in the action of AN-215 at a dose of
10–7 M. In addition, in co-cultured H-69 SCLC and H-157 non-
SCLC cells that do not express bombesin receptors, AN-215 was
targeted selectively to the bombesin receptors-positive H-69
SCLC cell line (Kiaris and Schally, in preparation).
Dose-limiting toxicity for AN-201 is essentially based on the
haematopoietic toxicity, and the maximum tolerated dose in male
nude mice is between 175 and 200 nmol kg–1 (Plonowski, et al,
1999). In this study AN-215 was less toxic than AN-201, but its
maximum tolerated dose was similar to that of AN-201, about
200 nmol kg–1. In contrast, 300 nmol kg–1 of AN-215 was well-
tolerated by Copenhagen rats in a most recent study (A Plonowski
et al, unpublished data), while 115–125 nmol kg–1 of AN-201 was
lethal (Schally and Nagy, 1999). A very similar toxicity pattern
was found in the case of our cytotoxic somatostatin analogue AN-
238 containing AN-201. Because AN-201 is linked to the peptide
carriers in these analogues through an ester bond, hydrolytic
cleavage of these conjugates by carboxylate esterase enzymes (EC
3.1.1.1) can occur in blood and in target tissues. These enzymes
are ubiquitous and show low substrate specificity. The half-lives of
cytotoxic peptide conjugates containing DOX-14-O-hemiglutarate
or 2-pyrrolino-DOX-14-O-hemiglutarate such as AN-215 in
serum of mice, rats and humans were found to be about 10,
30 and 120 min respectively (Plonowski et al, 1999). A better
tolerance of AN-215 by rats than by mice as compared to AN-201
may be due to the lower esterase activity in rats than in mice.
A less-pronounced esterase activity in blood may allow a more
effective targeting of the cytotoxic conjugate to receptor-positive
tissue. Besides the tumour cells, various normal, non-cancerous
cells in the central nervous system, lung, or the gastrointestinal
tract express high levels of receptors for bombesin. As our
previous studies on the toxicity and efficacy of cytotoxic somato-
statin analogue AN-238 indicate, these cells may not be irre-
versibly damaged by the DNA-intercalating antiproliferative
agent, 2-pyrrolino-DOX (AN-201), or the resting cells may be
able to reproduce the damaged cells (Plonowski et al, 1999).
Because the esterase enzyme activity is lower in human beings
than in rodents, an even better targeting of the cytotoxic agent to
receptor-positive tissue can be expected in humans.
This is the first report on the anti-tumour effects of targeted
cytotoxic analogue of bombesin AN-215 in human SCLC-derived
cell line. Our results demonstrate that in nude mice bearing
xenografts of H-69 SCLC, cytotoxic bombesin analogue AN-215
shows higher tumour inhibitory activity and lower toxicity than its
cytotoxic moiety AN-201. Our results suggest that tumours
expressing bombesin receptors, such as SCLC, could be treated
using targeted cytotoxic bombesin analogues.
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